NWPF

News ArchivesRead News

Mouse Model of Parkinson's Disease Shows Improved Brain Function, Motor Skills

Wednesday October 16, 2013

The Sacramento Bee - A paper published in the Journal of Neuroimmune Pharmacology shows that Revalesio's novel therapeutic RNS60 significantly improved biochemical and behavioral (movement) outcomes in a mouse model of Parkinson's disease (PD). The research was conducted by the laboratory of Dr. Kalipada Pahan at Rush University Medical Center.

The model used in the study generates Parkinson's-like symptoms through targeting dopaminergic neurons in the substantia nigra pars compacta, a region of the brain involved in controlling movement. The model produces neuronal death, loss of dopamine, and physical symptoms of the disease. The experiments conducted by Dr. Pahan's group demonstrate that treatment with RNS60 restored dopamine and provided a significant level of protection against neuronal death through upregulation of a protein called I kappa B alpha (IkBa).

"IkBa is an anti-inflammatory protein that helps with survival and function of neurons in neuroinflammatory conditions," said Dr. Pahan. "For therapeutic purpose, the best option would be to increase the level of this protein directly in the brain using a non-toxic medication. Remarkably, RNS60 treatment achieved this goal and thereby protected dopaminergic neurons in the mouse model of PD," Dr. Pahan said.

In addition to protecting the brain from the biochemical damage associated with PD, RNS60 also preserved the motor function of the animals, which the researchers assessed using numerous techniques. The ability to protect dopaminergic neurons, preserve striatal neurotransmitter function, and halt the progression of neurodegeneration and associated symptoms strongly suggest RNS60 as a promising therapeutic for PD and other neuroinflammatory diseases.

Revalesio's director of neurology research, Dr. Supurna Ghosh said, "In this study, RNS60's effect on the central anti-inflammatory mechanism in the glial cells of the brain is remarkable. Based on this work, and research previously published, we are hopeful RNS60 can have significant therapeutic effects in multiple neuroinflammatory and neuro-degenerative diseases. We are moving forward with additional research and human trials to further understand the therapeutic potential of RNS60."

A copy of the paper, Protection of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease by a Physically-Modified Saline Containing Charge-Stabilized Nanobubbles, can be found online at the Journal of Neuroimmune Pharmacology. (http://link.springer.com/article/10.1007/s11481-013-9503-3)

About RNS60: Revalesio is developing the use of RNS60 as a therapeutic that alters whole cell conductance through effects voltage-sensing membrane-bound proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

(16 Oct. 2013). The Sacramento Bee. Mouse Model of Parkinson's Disease Shows Improved Brain Function, Motor Skills Due to Revalesio's RNS60. www.sacbee.com.

Recent News

Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 18 - Fighting Parkinson's disease through dance
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show